Navigation Links
New Data Supports ConvaTec Negative Pressure Wound Therapy
Date:8/17/2009

SKILLMAN, N.J., Aug. 17 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the publication of new data demonstrating positive clinical results achieved with the Engenex((R)) Advanced Negative Pressure Wound Therapy (NPWT) system.

The Engenex((R)) NPWT System, utilizing low pressure (75 mm Hg) and EasyRelease(TM) dressings incorporating Bio-Dome(TM) Interface Technology, is designed to safely and effectively promote the healing of difficult wounds.

The case series study, published in the June issue of the journal Ostomy Wound Management, evaluated use of the next generation NPWT system in the management of complex surgical and traumatic wounds. Following the application of the NPWT system in a protocol of care, all three cases showed a marked progression toward wound healing, with reduced wound volume and development of healthy granulated tissue. Clinicians also observed that the dressing - developed specifically for use with the Engenex((R) )NPWT system - was well tolerated, with no tissue growth into the dressing, "little to no" disturbance of the granulation bed during dressing changes, and "little to no" bleeding or trauma on removal of the dressing.

"As our experience and these cases suggest, we believe that the Engenex NPWT System, with its low pressure profile and unique, non-adherent dressings, may represent an advance in this technology, possibly benefiting wound and patient outcomes," said author Cheryl Nease, PT, Memorial Health Center in Savannah, GA.

In December 2008, ConvaTec signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute the Engenex((R)) NPWT System incorporating Bio-Dome(TM) Interface Technology. The Engenex((R)) NPWT System is an innovative technology and engineering solution that utilizes the application of negative pressure to a wound to promote healing by creating controlled tissue strain and removing excess fluid, including wound exudate. Every aspect of the System, from the wound interface to the user interface, has been designed to attain optimal clinical outcomes as well as a simplified application and monitoring system for patient care.

"This publication is just the beginning in the development of our clinical evidence base in support of this advanced NPWT technology," said Marcus Schabacker, Chief Scientific Officer, ConvaTec. "As the researcher noted, the acceptable levels of observed pain, exudate management, minimal bleeding and wound bed disruption are important factors for clinicians managing complex wounds and for the patients they care for - and validates the excellent response we have been receiving from our initial customers."

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

Engenex is a registered trademark, and EasyRelease and Bio-Dome are trademarks of Boehringer Technologies L.P.

Our world is what we make of it is a trademark of ConvaTec Inc.

(C) 2009 ConvaTec Inc.

AP-007938-US

(1) Nease C. Using low pressure, negative pressure wound therapy for wound preparation and the management of split-thickness skin grafts in three patients with complex wounds. Ostomy Wound Management 2009;55(6)32-42.

    Contacts

    Punnie Donohue
    ConvaTec
    908-904-2151
    punnie.donohue@convatec.com

    Courtney Judd
    Weber Shandwick
    212-445-8365
    cjudd@webershandwick.com


'/>"/>
SOURCE ConvaTec
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health ... adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the shovels ... out the event photo slidehsow. , During the program, Richard H. Hart, MD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed ... data logger for each job, ensuring the best suited solution to meet regulatory ... data loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... 9.3 million people, or 10% over last year, according to data in the ... group policies was comparatively stable, with a slight decrease in risk-based groups and ...
Breaking Medicine News(10 mins):